FDA Approves Ivosidenib in IDH1-Mutated MDS
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.
Source: ajmc.com
Abbott Realtime News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Abbott Realtime. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Abbott Realtime Today - Breaking & Trending Today
FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndromes
The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.
Source: medscape.com
Tibsovo Approved for IDH1-Mutated Relapsed/Refractory Myelodysplastic Syndromes
The FDA has approved Tibsovo (ivosidenib) for the treatment of adults with relapsed or refractory MDS with a susceptible IDH1 mutation.
Source: empr.com
FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory...
Source: prnewswire.com
FDA Approves Tibsovo for Patients with R/R Myelodysplastic Syndromes
The Food and Drug Administration approved Tibsovo for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation.
Source: curetoday.com